 1.  Short title This Act may be cited as the  Vaccine Transparency Act of 2021 .
 2.  Reports to Congress on serious adverse events in connection with COVID–19 vaccines  (a)  In general  Not later than 60 days after the date of enactment of this Act, and every 60 days thereafter, the Commissioner of Food and Drugs and the Director of the Centers for Disease Control and Prevention, acting jointly, shall submit a report to the Congress on all serious adverse events that are reported—  (1)  to either agency pursuant to the Vaccine Adverse Event Reporting System or otherwise during the period covered by the report; and  (2)  in connection with a COVID–19 vaccine.  (b)  Initial report The reporting period of the initial report under subsection (a) shall begin on the date when the Commissioner of Food and Drugs first authorized emergency use of a COVID–19 vaccine under section 564 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–3 ). 
